It provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods, and agrochemical companies. The company was founded by Kiran Mazumdar-Shaw in 1978. The company operates across generics, biosimilars, and research segments with a global footprint.
Cyborg Score Rationale
Current market cap is $6.6B with 1.62B shares. As of 30-Sep-2025, Biocon has a trailing 12-month revenue of $1.9B. Strong biosimilars portfolio and contract manufacturing capabilities position Biocon as a significant player in emerging market biopharmaceuticals.
Top Insights
Diversified revenue streams across generics, biosimilars, and contract research services reduce dependency on single business segment
NSE-listed public company with $6.6B market capitalization and established investor presence in Indian markets
Strong manufacturing and R&D capabilities with contract manufacturing services for global pharmaceutical companies